AstraZeneca and MedImmune, its global biologics research and development arm, announced positive results for the phase III PACIFIC trial, a randomized, double-blinded, placebo-controlled multi-center trial of Imfinzi (durvalumab) as sequential treatment in patients with locally-advanced, unresectable non-small cell lung cancer who had not progressed following standard platinum-based chemotherapy concurrent with radiation therapy.
To access this subscriber-only content please log in or renew your subscription.
Looking for IP Login? Our IP Login system is now automatic. If your institution has a site license, please log in from on site or via your VPN to access this content.
Login Subscribe
Looking for IP Login? Our IP Login system is now automatic. If your institution has a site license, please log in from on site or via your VPN to access this content.
Login Subscribe